Filtered By: Topstories
News

FDA warns vs. 5 unregistered drug products


The Food and Drug Administration warned the public against five unregistered drug products that may be sold in the market.

In Advisory 2015-034 dated June 23, the FDA said these products may "pose potential danger or injury to the consuming public."

Health Secretary and OIC FDA director general Janette Garin said these products include:

- Moxifloxacin Hydrochloride (Moxibright) 5 mL Eye Drops
- Moxifloxacin Hydrochloride + Dexamethasone Sodium Phosphate (Moxibright DM) 5 mL Eye Drops
- Carboxymethyl Cellulose Sodium + Glycerin (Tearbright Plus) 10 mL Eye Drops
- Gatifloxacin + Prednisolone Acetate (Gatsun-P) 5 mL Eye Drops
- Moxifloxacin Hydrochloride (Occumox) 5 mL Eye Drops

The FDA reminded the public the importation, selling or offering for sale of these products will violate Republic Act No. 9711.

It said it has ordered field regulatory operations officers to seize these unregistered drug products from the market.

"All establishments and outlets are hereby warned against selling and/or dispensing the above identified products. Anyone found selling the said products will be penalized," it said.

Meanwhile, the FDA asked local government units and law enforcement agencies to ensure these products are not sold or offered for sale in their areas.

It also reminded consumers to buy medications only from FDA-licensed establishments and to look for the FDA registration number on the product label.

Those who want to report the sale or distribution of the unregistered health products may email FDA viareport@fda.gov.ph or call it at (02)807-8275.

Those who may have adverse drug reactions may report to FDA via www.fda.gov.ph/adr-report-new and fill out all the required fields. — Joel Locsin/LBG, GMA News